Merck Acquires Prometheus Biosciences for $10.8 Billion

The deal for Prometheus is expected to close in the third quarter

By
Terry Lane
Terry Lane
Full Bio
Terry has 25 years experience in journalism and communications, reporting on a range of topics that include personal finance, telecommunications, Congress, government regulations, and criminal justice. He has also worked on technology, energy, and environmental policy issues as a congressional press secretary and owned and published a local community newspaper in North Carolina.
Learn about our editorial policies
Updated April 17, 2023
Merck

Getty Images

Key Takeaways

  • Merck agreed to acquire Prometheus Biosciences in a deal worth $10.8 billion.
  • Shares of Prometheus Biosciences were up 70% in early trading on Monday following the announcement.
  • Merck shares dipped slightly on the news.

Shares of Prometheus Biosciences (RXDX) jumped on Monday after the maker of intestinal inflammatory disease treatments said it will be acquired by Merck, as the drug maker seeks to diversify its product line. 

In a deal worth $10.8 billion, Merck (MRK) agreed to acquire Prometheus Biosciences at a price of $200 per share, a 75% premium to Friday's closing price. The deal for Prometheus is expected to close in the third quarter.

Prometheus Biosciences Chair and CEO Mark McKenna said that deal would maximize the potential for its lead product, a drug aimed to target intestinal inflammation diseases like ulcerative colitis and Crohn’s disease, “while continuing to apply our technology and expertise to fuel further discoveries to address the needs of patients with immune disorders.” 

The acquisition will add diversity to Merck’s portfolio as it seeks to tap into new markets, said Robert M. Davis, the company’s chair and chief executive.

“The agreement with Prometheus will accelerate our growing presence in immunology where there remains substantial unmet patient need,” Davis said. 

Shares of Prometheus Biosciences were up 70% in early trading on Monday following the announcement. Merck shares dipped slightly on the news. 

RXDX on TradingView

TradingView
Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.

  1. GlobeNewsWire. “Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.”

Take the Next Step to Invest
×
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.
Service
Name
Description